Local intramuscular administration of ANG1 and VEGF genes using plasmid vectors mobilizes CD34+ cells to peripheral tissues and promotes angiogenesis in an animal model - 09/10/21
, Diana Kupczyńska, Katarzyna Kulikowska, Bartłomiej Strzelec, Dariusz Janczak, Piotr BarćBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Introduction |
Patients with peripheral artery disease have poor prognosis despite advances in vascular surgery. Therefore, attempts have been made at using gene and cell therapy to stimulate angiogenesis in the lower limbs in patients with critical lower limb ischemia (CLI).
Methods |
The study included 30 rats divided into 3 groups. An intramuscular injection of a therapeutic gene or cells in the right hind limb was administered in each group: angiopoietin-1 (ANG1) plasmid in group 1, ANG1/vascular endothelial growth factor (ANG1/VEGF) bicistronic construct in group 2, and naked plasmid in group 3 (control). After 3 months of follow-up, tissue samples were harvested, and vessels that stained positively for CD34 cells were quantified.
Results |
The highest CD34+ cell count was noted in the ANG1/VEGF group (98.26 cells), followed by the ANG1 group (80.31) and control group (47.93). The CD34+ cell count was significantly higher in the ANG1/VEGF and ANG1 groups than in the control group. There was no significant difference in the CD34+ cell count between the ANG1/VEGF and ANG1 groups.
Conclusion |
Our study confirmed that therapy with ANG1 plasmid alone or ANG1/VEGF bicistronic construct is safe and effective in a rat model. The therapy resulted in the recruitment of more CD34+ vascular endothelial cells than in the control group receiving naked plasmid.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | ANG1VEGF and ANG1 plasmid stimulate angiogenesis in rat muscles. |
• | ANG1/VEGF bicistronic plasmid outperforms ANG1 plasmid in terms of neoangiogenesis. |
• | Neoangiogenesis was confirmed by recruitment of CD34+ vascular endothelial cells. |
• | ANG1/VEGF and ANG1 gene therapy is safe and effective in an animal model. |
Keywords : Gene therapy, ANG1, VEGF, CD34+
Plan
Vol 143
Article 112186- novembre 2021 Retour au numéro
Article précédent
- Anti-psoriatic and anti-inflammatory effects of Kaempferia parviflora in keratinocytes and macrophage cells
- Mingkwan Na Takuathung, Saranyapin Potikanond, Siriwoot Sookkhee, Pitchaya Mungkornasawakul, Thanathorn Jearanaikulvanich, Kittinan Chinda, Nitwara Wikan, Wutigri Nimlamool
- Transcriptome analysis to reveal the mechanism of the effect of Echinops latifolius polysaccharide B on palmitate-induced insulin-resistant
- Ran Li, Yajuan Xia, Zhenzhen Gao, Yue Song, Zhiwei Guo, Ying Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?